Prevention and management of complications in robotic radical gastrectomy

WANG Ye，NAN Hai’ou，GE Miaomiao，WANG Haifeng，PAN Huafeng，SUN Chenhua，WANG Gang，JIANG Zhiwei

Abstract:  With the extensive development of minimally invasive technology in gastric cancer surgery，Da Vinci robot⁃assisted radical gastrectomy has also attracted increasing attention. The application of robotic technology in gastric cancer surgery can .....

Chin J Clin Res,2026,39(2): 173-177.  [PDF]

• A retrospective cohort study of total laparoscopic Ivor Lewis esophagectomy versus open esophagectomy 

  YU Ao，ZHOU Yong，ZHAO Gefei，DAI Bo

  Chin J Clin Res,2026,39(2):178-182. [PDF]

  
  

• Construction of prediction model for perforation risk in endoscopic submucosal dissection of early

  gastric cancer 

  GUAN Zhong，ZUO Xueyong，ZHANG Yansong

  Chin J Clin Res,2026,39(2):183-187. [PDF]

  
  

• Expression and clinical significance of isoprenyl carboxyl methyltransferase in gastric cancer tissues 

  JING Tiancong，MA Shangxian，LI Yuanxiao，DAI Xingxing，NIU Shaomin，MA Hanwei

  Chin J Clin Res,2026,39(2):188-192. [PDF]

• Expression of MAD2L1 and miR⁃28⁃5p in gastric cancer tissues and their clinical significance  

  CUI Guangjie，LIU Yuanming，CHEN Jiaqi，LU Yang，TAO Yunxia，GAO Chao 

  Chin J Clin Res,2026,39(2):193-198.  [PDF]

• Construction and validation of LODDS⁃based nomogram for prognosis of stageⅠ-Ⅱ gastric signet ring 

  cell carcinoma  

  DU Yuan，LIU Lei，WANG Cenzhu，DING Yucheng，FENG Shuhan，QIAN Ji 

  Chin J Clin Res,2026,39(2):199-204. [PDF]

  
  

• Sorafenib combined with transcatheter arterial chemoembolization and radiofrequency ablation in the

  treatment of postoperative recurrence of hepatocellular carcinoma    

  CAI Jiameng，LI Mengdi，WANG Renping，DU Chunhai 

  Chin J Clin Res,2026,39(2):205-210.  [PDF]

  
  

• Efficacy and safety of H1 receptor antagonists combined with PD⁃1 inhibitors and chemotherapy in

  advanced lung squamous cell carcinoma   

  ZHU Yizhi，ZHANG Zheyuan，YUAN Luhongying，CHEN Yiting，MENG Lijuan

  Chin J Clin Res,2026,39(2):211-215.  [PDF]

• The relationship between PD⁃1 inhibitor treatment⁃related thyroid dysfunction and serum IL⁃21 levels of 

  non⁃small cell lung cancer   

  ZHAI Yang，CHEN Qian，LIU Jia，CHANG Linhan，LI Jingjin

  Chin J Clin Res,2026,39(2):216-220. [PDF]

• Influencing factors and prediction model of acquired drug resistance after treatment with PD⁃1/PD⁃L1 

  inhibitors in patients with non⁃small cell lung cancer    

  ZHAO Lina，WANG Zhaoyang，WANG Bu 

  Chin J Clin Res,2026,39(2):221-225.  [PDF]

  
  

• Thermal ablation combined with gemcitabine and cisplatin regimen in patients with non⁃small cell  

  lung cancer  ffoot ulcers    

  SONG Jian，LIU Haiyan，CHEN Xiaolin，SONG Miaomiao，WANG Hui，XU Feng 

  Chin J Clin Res,2026,39(2):226-230.  [PDF]

  
  

• Analysis of the use of novel antitumor drugs in lung cancer treatment at Nanjing Chest Hospital from  

  2019 to 2023    

  WANG Fang，HUANG Peiyan，FANG Shencun 

  Chin J Clin Res,2026,39(2):231-236.  [PDF]